NEWS

2024.09.05
Press Releases

Announcement of First Transplantation in the Domestic Phase II Clinical Trial of the AE101 Regenerative Medicine Cell Product

We are pleased to inform you that the first patient in our domestic Phase II clinical trial of AE101, a regenerative medicine cell product under development by ActualEyes Inc., has successfully received the transplantation. AE101 is designed for the treatment of bullous keratopathy (see Note 1). We are also pleased to report that the necessary safety evaluations have been completed, allowing for the continuation of the trial with subsequent patients.

PDF

2024.03.27
Press Releases

Submission of Clinical Trial Protocol Notice for Corneal Endothelial Therapy Cell Therapy, “AE101”

ActualEyes Inc. is pleased to announce the submission of the Phase II clinical trial protocol for “AE101,” a cutting-edge therapy for the treatment of bullous keratopathy, to the Pharmaceuticals and Medical Devices Agency (PMDA). After PMDA’s 30-day investigation of the clinical trial protocol, we anticipate commencing the clinical trial.

PDF

2022.11.18
Press Releases

Announcement of Licensing by Japan Innovative Therapeutics, Inc. of Corneal Endothelium Therapeutic Agents

PDF

2022.08.08
Press Releases

Aiming at Early Commercialization of Regenerative Medicine for Corneal Endothelium Manufacturing of regenerative medical product candidate AE101 starting at J-TEC

PDF

2022.08.03
Press Releases

Announcement of Appointment of Outside Director

PDF

 

 

This website uses cookies for the purpose of operating our services and improving the user experience. For details, please refer to our privacy policy. By clicking on the “Agree” button or continuing to use our website, you will be regarded as having agreed to our use of cookies.

Agree